Myrexis (FRA:R9M) Capital Expenditure : €0.00 Mil (TTM As of Jun. 2013)

View and export this data going back to . Start your Free Trial

What is Myrexis Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Myrexis's cash flow for capital expenditures for the three months ended in Jun. 2013 was €0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Jun. 2013 was €0.00 Mil.

Myrexis Capital Expenditure Historical Data

The historical data trend for Myrexis's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myrexis Capital Expenditure Chart

Myrexis Annual Data

Trend

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Capital Expenditure

Get a 7-Day Free Trial

-5.27

-1.75

-0.07

-0.04

Myrexis Quarterly Data
	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13
Capital Expenditure	Get a 7-Day Free Trial															-	-	-	-	-

Myrexis Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Jun. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Myrexis (FRA:R9M) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (FRA:R9M) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, Suite 2260, New York, NY, USA, 10020

Website

http://www.myrexis.com

Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.

Myrexis (FRA:R9M) Headlines

No Headlines